Management emphasized that its drug-discovery approach combines proprietary biological data, AI models and experimental validation in a continuous “lab-in-the-loop” system. Recursion also cited the potential for more than $300 million in additional development, commercialization and sales milestones for each future small-molecule program under the collaboration. AI Platform and Spending PlansRecursion said it has generated and aggregated more than 50 petabytes of multimodal biological data. About Recursion Pharmaceuticals (NASDAQ:RXRX)Recursion Pharmaceuticals, Inc (NASDAQ: RXRX) is a biopharmaceutical company that combines advanced automation, artificial intelligence and high-throughput biology to discover and develop novel therapeutics. At the core of Recursion’s offering is its digital biology platform, which captures billions of cell images under varying chemical and genetic perturbations.